Skip to main content

Table 2 Comparison of substrate changes between non-human-primates and humans. Protein ratio of BACE inhibition versus placebo/vehicle of sSEZ6, sIL6ST/sgp130, and sAPPβ detected by mass spectrometry (MS), Western Blotting (WB) or immunoassay ± standard deviation in %

From: The Alzheimer’s disease-linked protease BACE1 modulates neuronal IL-6 signaling through shedding of the receptor gp130

Species

Macaca mulatta

Homo sapiens

Inhibitor

100 mpk MBI-4

3 mpk Verubecestat

100 mg

Verubecestat

Method

MSa

WB/immunoassay

MSa

WB/immunoassay

sSEZ6

35.9 ± 1.38%

14.0 ± 4.8%b

38.7 ± 7.7%

25.3 ± 14.2%d

sIL6ST/sgp130

46.1 ± 6.7%

21.8 ± 2.0%b

60.1 ± 8.6%

40.2 ± 8.5%e

sAPPβ

7.1 ± 7.4%b / 18.4 ± 4.8%c

21.7 ± 4.7%f

  1. amass spec data are taken from Fig. 1
  2. bWestern Blotting data are taken from Fig. 1
  3. cimmunoassay data for sAPPβ are taken from [27] for non-human primates
  4. dWestern Blotting data are taken from Fig. 2
  5. eELISA data are taken from Fig. 2
  6. fimmunoassay data for sAPPβ are taken from [28] for humans